SRT1720 HCl

For research use only. Not for use in humans.

目录号:S1129

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

SRT1720 HCl是一种选择性的SIRT1激活剂,无细胞试验中EC50为0.16 μM,对SIRT2和SIRT3的作用弱230倍以上。SRT1720 还可诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1960.55 现货
RMB 1400.82 现货
RMB 7964.73 现货
RMB 20229.3 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SRT1720 HCl发表文献151篇:

产品安全说明书

Sirtuin抑制剂选择性比较

生物活性

产品描述 SRT1720 HCl是一种选择性的SIRT1激活剂,无细胞试验中EC50为0.16 μM,对SIRT2和SIRT3的作用弱230倍以上。SRT1720 还可诱导自噬。
靶点
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
体外研究

SRT1720抗最近的乙酰化酶同系物SIRT2 (EC1.5为37 μM)和SIRT3 (EC1.5 > 300 μM)的最大激活率达781%。SRT1720在氨基末端催化区的变构位点结合到SIRT1酶-肽底物复合物上,降低乙酰化底物的米氏常数值。用SRT1720处理一周后,饲喂的葡萄糖水平降低,处理三周后,饲喂的葡萄糖水平进一步降低,持续处理10周。Rosiglitazone激活PPARγ,已经用于治疗II型糖尿病;而与Rosiglitazone相比,在进行腹膜葡糖糖耐量试验时,用SRT1720处理导致葡萄糖明显降低。SRT1720对用无糖食物喂养的鼠没有作用效果,显示出药理学SIRT1的激活不会产生低血糖。与Rosiglitazone相似,用SRT1720处理4周,明显降低高胰岛素血症,使升高的胰岛素水平恢部分复正常SRT1720处理腓肠肌,通过测定柠檬酸合酶活性发现线粒体各项能力上升15%。[1]高浓度 SRT1720 (15 μM)诱导正常细胞活力轻微下降,约10-20%。SRT1720明显抑制VEGF依赖的 MM 细胞迁移。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  MkPJSpVv[3Srb36gRZN{[Xl? NHfoWmg1yqEQvF2= MVSzNOKhdWmw MlrPSG1UVw>? MX\pcoR2[2W|IHHjeZRmKFOLUmSxJIFkfGm4YYTpc47DqA>? NXHDWZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yOVQyODRpPkK2NlU1OTB2PD;hQi=>
MC3T3-E1 M132OmZ2dmO2aX;uJGF{e2G7 M{DRclExKML3TdMg M{XOeVEhcA>? MoTCdoVlfWOnczD0bIUhXEeILd8yMZN1cW23bHH0[YQhXkWJRjDy[Yxm[XOnIHnuJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XMEoB?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|Nkm3PEc,OjZzM{[5O|g9N2F-
MC3T3-E1 NUHIfm4{TnWwY4Tpc44hSXO|YYm= MljBNVAhyrWPwrC= MXuxNkBp MVHy[YR2[2W|IITo[UBXTUeIIH3SUmEh\XiycnXzd4lwdiCuZY\lcJMhe3SrbYXsZZRm\CCkeTDUS2Yu|rJ? NF;wcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzOlk4QCd-Mk[xN|Y6Pzh:L3G+
MC3T3-E1 MYfGeY5kfGmxbjDBd5NigQ>? NGHRXoszOCEQvF2= MlTJNUBp Mljhd5VxeHKnc4Pld{B1cGViVFfGMe6zNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB2ND;wOFIhVUGSIHvpcoF{\SCxcjDTRXBMN0qQSx?= MnywQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[5O|goRjJ4MUO2PVc5RC:jPh?=
WE-68 M1Xle2Fxd3C2b4Ppd{BCe3OjeR?= NUP0PG1KOC1{NDFOwG0> MnzqNlQhcA>? MUnpcoR2[2W|IHPlcIwh\GWjdHigbY4h\G:|ZTDk[ZBmdmSnboTsfS=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-ES-1 NHzaZohCeG:ydH;zbZMhSXO|YYm= M1y5XlAuOTBizszN M2O5UFI1KGh? MVXpcoR2[2W|IHPlcIwh\GWjdHigbY4h\G:|ZTDk[ZBmdmSnboTsfS=> MkDCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
SK-N-MC  NXrsXnlnSXCxcITvd4l{KEG|c3H5 MV2wMVIvPSEQvF2= NFzWTIMzPCCq NXvNT5VncW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? M3\BRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
WE-68 M2\2XGZ2dmO2aX;uJGF{e2G7 M1y4OVIxKM7:TR?= MXSwMVI1KGh? M4DMOYFkfGm4YYTld{Bk[XOyYYPlJFMwPw>? NXT0e4hSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-ES-1 MkLLSpVv[3Srb36gRZN{[Xl? NFn5OmIyOCEQvF2= NEfrdXUxNTJ2IHi= MVHhZ5RqfmG2ZYOgZ4F{eGG|ZTCzM|c> Ml3SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
SK-N-MC  MVHGeY5kfGmxbjDBd5NigQ>? NGLibVg{KM7:TR?= NGXoTVgxNTJ2IHi= Mk\lZYN1cX[jdHXzJINie3Cjc3WgN{84 MkTYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNUW4NFUoRjJ4MEW1PFA2RC:jPh?=
NRK-49F NVLwbJdLTnWwY4Tpc44hSXO|YYm= M3HEWFDjiJN{wrFOwG0> NVz4eFZwOzZiaB?= NVTFNWVZcW6lcnXhd4V{KGW6cILld5Nqd25ib3[g{tEuW02DIHHu[EBncWK{b37lZ5RqdiCmb4PlJIRmeGWwZHXueIx6 MkDDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkKwNFMoRjJ4MEKyNFA{RC:jPh?=
NRK-49F M3T0OGZ2dmO2aX;uJGF{e2G7 NEfiUYEx6oDVMtMg{txO MUizOkBp M33yc4VvcGGwY3XzJJBpd3OyaH;yfYxifGmxbjDv[kBGT0[UIHHu[EBRTEeIUt8yxsA> NUjnVmNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
NRK-49F M1W2b2Z2dmO2aX;uJGF{e2G7 NWnCSm9JOOLCk{NCpO69VQ>? MnfZN|YhcA>? MnzS[Y5p[W6lZYOgV3RCXDNicHjvd5Bpd3K7bHH0bY9v NIPxSIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyNlAxOyd-Mk[wNlIxODN:L3G+
RAW264.7 Mor6SpVv[3Srb36gRZN{[Xl? M4rXVlEh|ryP MUS2JIg> MXP1dJJm\3WuYYTld{B1cGVicnXkeYNm\CCVSWLUNUBxem:2ZXnuJI9zKG2UTlGgcIV3\Wy|IHL5JIhq\2hiZ3z1Z49{\Q>? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7M{m5OUc,OjV5OUO5PVU9N2F-
MCF10A NF32UlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTSRYYxNTJyIN88US=> M1;wWVI1KGh? M4PWN5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MCF-7 NWS4UoU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVSwMVIxKM7:TR?= NUDVe3NkOjRiaB?= NWDrd29kemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NFjRTo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
T47D M3;ubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDsNE0zOCEQvF2= MY[yOEBp MYLy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NWHXendbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
SKBR3 NHK3bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXuwMVIxKM7:TR?= NUfHU41kOjRiaB?= M3\nc5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MDA-MB-231 NGrJRYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMVIxKM7:TR?= M4C1SVI1KGh? NW\LOGh7emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
SUM149 NWXPO|lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BRlAuOjBizszN NWGzPY9IOjRiaB?= M3jG[5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
HS578T NFrCN|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTJPGIxNTJyIN88US=> M1\MVlI1KGh? NUDZe2xuemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
BT20 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVmwMVIxKM7:TR?= NVjlcYsyOjRiaB?= MVXy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NVm0eI5HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
A459 NWraPXozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTad5MxNTJyIN88US=> M1O2TlI1KGh? NXnDWFZyemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NUnvWFljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
HCT116 NGqxOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXywMVIxKM7:TR?= NFK0c4EzPCCq NUXWb2RZemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M1P4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
Neu MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfuPYY5OC1{MDFOwG0> M2\ocFI1KGh? MVfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NX:4eWxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
MDA-MB-231 MW\GeY5kfGmxbjDBd5NigQ>? NHHwdJU2KM7:TR?= MWW4JIg> NHPlblJqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDhZ4llcWNidnXzbYN2dGG{IH;y[4Fv\WyuZYO= NFnXO209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MDA-MB-231 NEDnT45HfW6ldHnvckBCe3OjeR?= NILtcYs2KM7:TR?= M2XUR|E3KGh? MUfpcoR2[2W|IHz5d49{d22jbDDt[Y1jemGwZTDw[ZJu\WGkaXzpfoF1cW:w MlXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
MC3T3-E1 MmjESpVv[3Srb36gRZN{[Xl? MVOxNEDPxE1? MnjWOlAhdWmwwrC= MXPzeZBxemW|c3XzJJRp\SCIR1[tNk1{fGmvdXzheIVlKG:|dHXvdJJwfGWpZYLpckBz\WynYYPl MlPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUCwPVUoRjJ3MkmwNFk2RC:jPh?=
MC3T3-E1 MWPGeY5kfGmxbjDBd5NigQ>? NEHmWGEyOCEQvF2= M{D1NlYxKG2rbtMg MVvheJRmdnWjdHXzJJRp\SCIR1[tNk1qdmS3Y3XkJI9{fGWxcILveIVo\XKrbjDtVm5CKGW6cILld5Nqd25? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7MEC5OUc,OjV{OUCwPVU9N2F-
MC3T3-E1 NGDXfZhHfW6ldHnvckBCe3OjeR?= NYj1V3RyOTBizszN Mmj0OlAhdWmwwrC= M1LJW4F1fGWwdXH0[ZMhfGinIF\HSk0zNWmwZIXj[YQhd3O2ZX;wdo91\WencnnuJI1TVkFiZYjwdoV{e2mxbh?= NGX0TJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1 MYTGeY5kfGmxbjDBd5NigQ>? M1;HeFExKM7:TR?= M3XxN|YxKG2rbtMg NXXFPY1Le3WycILld5NmeyC2aHWgRm1RNTRvc4TpcZVt[XSnZDDWSWdHKHKnbHXhd4U> M4TUTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEO1OFQ1Lz5{NESzOVQ1PDxxYU6=
MC3T3-E1 MYDGeY5kfGmxbjDBd5NigQ>? M{[0flExKM7:TR?= MY[2NEBucW8EoB?= MVXzeZBxemW|c3XzJJRp\SCSR1[y{tEue3SrbYXsZZRm\CCRUFegdoVt\WG|ZR?= NFvGNYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzN|M{Pid-MkSzN|M{OzZ:L3G+
MC3T3-E1 MXjGeY5kfGmxbjDBd5NigQ>? NH\nXJMyOCEQvF2= MnrhOlAhdWmwwrC= M{ixeJJm\HWlZYOgeIhmKFCJRkNOtU1{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2V? MoDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
MC3T3-E1 NHj0ZWVHfW6ldHnvckBCe3OjeR?= M36xfFExKM7:TR?= NGDDW4M3OCCvaX9CpC=> MlTOZZR1\W63YYTld{B1cGViUFfGNu6yNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigUWVMOS9{IHHu[EBT[WZvMR?= NV\5RVR6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN|M{OzZpPkK0N|M{OzN4PD;hQi=>
RPE NFT0XnFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mnf4OUDDvU1? M{XGeFEhcA>? NXHvUFRt[XS2ZX71ZZRmeyCRQd8yMYlv\HWlZXSg[IVkemWjc3Wgc4Yh[2WubDD2bYFjcWyrdIm= NHnMXlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECzOlk{QCd-MkSwN|Y6Ozh:L3G+
9607 NVfVOIpNS2WubDDWbYFjcWyrdImgRZN{[Xl? MkDvNUDPxE1? M3m1VlM3KGh? NVnBNnk1cW6lcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClb33wZZJm\CC5aYToJI1mdGG2b37pckBidG:wZR?= M{ewclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K2PVQ6Lz5{M{eyOlk1QTxxYU6=
9607 NV3NbY5KTnWwY4Tpc44hSXO|YYm= NUXYW41oOSEQvF2= NUHYb|hsOzZiaB?= NVvvU4dMcW6lcnXhd4V{KFOLUmSxJIFv\CCmZXPy[YF{\WRiYXPleJlt[XSnZD3wOVMh\XiycnXzd4lwdg>? NFfWWIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyOlk1QSd-MkO3NlY6PDl:L3G+
RPMI.8226 Ml2wR4VtdCCYaXHibYxqfHliQYPzZZk> NHLyNYs4NzFyIN88US=> NHHCV40zPCCq M1\CcYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M1nqfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
U266 MlT1R4VtdCCYaXHibYxqfHliQYPzZZk> M3z3S|cwOTBizszN MnP5NlQhcA>? MVTk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= NV:xe25kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
MM.1S M4WwR2NmdGxiVnnhZoltcXS7IFHzd4F6 M2S1SVcwOTBizszN M13zRlI1KGh? MlHh[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 NX[4V2hYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
KMS12 MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{f3ZlcwOTBizszN Ml7aNlQhcA>? MoDU[IVkemWjc3XzJJZq[WKrbHn0fUBkd26lZX70doF1cW:wIHTldIVv\GWwdHz5 MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
LR5 NV3XO25SS2WubDDWbYFjcWyrdImgRZN{[Xl? M{\iSVcwOTBizszN MYqyOEBp NYrDdpBw\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 NFW0fY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
MM.1R MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUi3M|ExKM7:TR?= MWWyOEBp M{HZbYRm[3KnYYPld{B3cWGkaXzpeJkh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
Ina6 MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWG3M|ExKM7:TR?= NEW5U5QzPCCq NYe3V|RX\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 MnzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
RPMI-8226 M1\FXWFxd3C2b4Ppd{BCe3OjeR?= NWPvfFVOPy9zMDFOwG0> MlXtNlQhcA>? MVTpcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6lcnXhd4UhcW5idHjlJGFvdmW6aX6gWkswWEokiKNCpIFxd3C2b4Ppdy=> M1f6N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
MM.1R  NF\vRWVCeG:ydH;zbZMhSXO|YYm= M1PDVVcwOTBizszN Mlq2NlQhcA>? MlPnbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> NH\5Rlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm1NFczQCd-MkG5OVA4Ojh:L3G+
H411EC3 Ml3zSpVv[3Srb36gRZN{[Xl? MkHzOVAwOTByIH7N MUO2JIg> M4jNVYlv[3KnYYPld{BUUVKWMTDhZ5Rqfmm2eTDpckB1cGVicILld4Vv[2Vib3[gWHNCNCCSRWDDT{Bi[3Srdnn0fUwhdVKQQTDs[ZZmdHNib3[gVINsOSCjbnSgVIdkOc7zLDDhcoQh\WyndnH0bY5oKGeudXPvd4UheHKxZIXjeIlwdg>? M3roT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
hepatocytes M4PTSmZ2dmO2aX;uJGF{e2G7 NUXtWHp3OTBibl2= NW[zeJpUPiCq MlPnbY5kemWjc3XzJHNKWlRzIHHjeIl3cXS7IHnuJJRp\SCycnXz[Y5k\SCxZjDUV2EtKFCHUFPLJIFkfGm4aYT5MEBuWk6DIHzleoVteyCxZjDQZ4syKGGwZDDQ[4My|rFuIHHu[EBmdGW4YYTpcoch\2y3Y3;z[UBxem:mdXP0bY9v Ml;IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MUKwPVYoRjJzMkGyNFk3RC:jPh?=
hepatocytes NXTPU5VpTnWwY4Tpc44hSXO|YYm= NFnSR3gyOCCwTR?= MnX3OkBp M4fybYlv[3KnYYPld{BJdWelctMgZY5lyqCDY3RCpIdmdmViZYjwdoV{e2mxbh?= MlvVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{MUKwPVYoRjJzMkGyNFk3RC:jPh?=
U2OS NUTGWoh4TnWwY4Tpc44h[XO|YYm= M4PaUVAvOTBidV2= MWrBZ5RqfmG2aX;uJI9nKFOLUmSxJIlvKGi3bXHuJHUzV1NiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdFU{KGSnYXPleJlt[XSrb36gcIV3\WxiYYSgNE4yOCC3TR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB2NkSwPUc,OThyNE[0NFk9N2F-
A673 M37FO5FJXFNiYYPzZZk> NXzEUGhOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFG2O|Mh[2WubIO= M3nMcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY NWezZlV7eUiWUzDhd5NigQ>? NVWxeGM2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO= MnHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 MVHxTHRUKGG|c3H5 MUXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD MWHxTHRUKGG|c3H5 M3TsW5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MnPNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) MXLxTHRUKGG|c3H5 NFnISWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= NH;2Z3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NEfMVYdyUFSVIHHzd4F6 NIPKNIVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 MWjxTHRUKGG|c3H5 NYTWbHNleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MmHFdWhVWyCjc4PhfS=> MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? NFL4WIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 NGTrfnZyUFSVIHHzd4F6 Ml7WdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqM{CgZ4VtdHN? NUPyWZBKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5 MVXxTHRUKGG|c3H5 NW\oWVRreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz NF;hXVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MljIdWhVWyCjc4PhfS=> MlizdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NXLFSJJ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1; 

PubMed: 26655844     


SU86.86 cells were transfected with control siRNA, SIRT1 siRNA#1, or DBC1 siRNA. 24 hours after transfection, cells were re-plated and allowed to attach for 24 hours. Cells were then treated with vehicle (control) or 5 μM SRT1720 for 16 hours. Expression 䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙

26655844
Immunofluorescence
Cathepsin B; 

PubMed: 26655844     


SU86.86 cells were incubated with vehicle or 5 μM SRT1720 for 5 hours for LysoTracker Red labeling and 16 hours for cathepsin B immunofluorescence, followed by DAPI staining.

26655844
Growth inhibition assay
Cell viability ; 

PubMed: 25411356     


MTT viability assay of cancer cell lines treated with different doses of SRT1720 for 24 hours. 

25411356
体内研究 在DIO鼠中实施摄热量限制包括改善胰岛素敏感性,使葡萄糖和胰岛素水平维持正常,及提高线粒体能力后,可观察到SRT1720模拟一些功能。此外,在饮食导致的肥胖和遗传肥胖鼠中,SRT1720提高胰岛素敏感性,降低血浆葡萄糖,及提高线粒体能力。因此,SRT1720是有前途的新型治疗剂,可用于治疗像II型糖尿病之类的疾病。与提高的葡萄糖耐量相一致,在SRT1720处理的fa/fa鼠中,维持血糖正常所需的葡萄糖注入率(GIR)大约为35%, 全部的葡萄糖处理效率提高大约为20%。 [1] SRT1720作用于动物肿瘤模型研究时,抑制多发性骨髓瘤生长。SRT1720提高Bortezomib或Dexamethasone的毒性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

SIRT1荧光偏振实验:

在SIRT1 FP试验中,使用从p53序列中得到的含20个氨基酸的肽段 (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly-Lys(MR121或 Tamra)-Glu-Glu-NH2)。肽段N端与生物素相连,C端用荧光标记修饰。监测酶活的反应是酶活偶联反应,第一步反应为SIRT1催化的脱乙酰反应,第二步反应为在新暴露的赖氨酸残基处进行胰蛋白酶催化的分裂。为了突出底物和产物的多种区别,加入链酶亲和素,反应终止。FP测试的敏感性可用来鉴定SRT1720。进行荧光偏振反应环境如下:0.5 μM 肽底物, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-醋酸盐(pH 为8), 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl2, 5 mM DTT, 0.025% BSA, 及0.15 mM烟碱。 反应在37oC温育,加入烟碱终止反应,加入胰蛋白酶分裂脱乙酰底物。加入链酶亲和素在37oC温育。在650 nm 和680nm 处测定荧光偏振。
细胞实验:[2]
- 合并
  • Cell lines: 人类血管内皮细胞(HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2小时
  • Method: 使用Transwell迁移实验测定迁移率。通过基底膜的毛细血管样管结构形成试剂盒检测体外血管生成。用于内皮血管生成实验,从Clonetics获得的人类血管内皮细胞(HUVEC),保存在含5% FBS的内皮细胞生长培养基中。使用台盼蓝拒染法测定HUVEC细胞活力,观察到用SRT1720处理的细胞死亡率小于5%。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带MM.1S细胞的Chase-SCID鼠
  • Dosages: 200 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 506.02
化学式

C25H23N7OS.HCl

CAS号 1001645-58-4
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • 回答:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

相关Sirtuin产品

Tags: 购买SRT1720 HCl | SRT1720 HCl供应商 | 采购SRT1720 HCl | SRT1720 HCl价格 | SRT1720 HCl生产 | 订购SRT1720 HCl | SRT1720 HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID